These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 6511457)

  • 1. Neuroendocrinological studies of Parkinson disease.
    Kito S; Itoga E; Yamamoto M
    Hiroshima J Med Sci; 1984 Sep; 33(3):323-9. PubMed ID: 6511457
    [No Abstract]   [Full Text] [Related]  

  • 2. [Endocrinological studies on Parkinson's disease (author's transl)].
    Yamamoto M; Kito S; Itoga E; Kishida T; Kamiya K
    Rinsho Shinkeigaku; 1979 Jul; 19(7):413-22. PubMed ID: 115632
    [No Abstract]   [Full Text] [Related]  

  • 3. The endocrinology of extrapyramidal system disorders.
    Kirkpatrick B; Tamminga CA
    Endocrinol Metab Clin North Am; 1988 Mar; 17(1):159-72. PubMed ID: 2967753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypothalamic dysfunction in Parkinson's disease patients.
    Otake K; Oiso Y; Mitsuma T; Hirooka Y; Adachi K
    Acta Med Hung; 1994; 50(1-2):3-13. PubMed ID: 7638039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetic and pharmacodynamic aspects of L-DOPA treatment and dopadecarboxilase inhibitors and dopaminergic antagonists in Parkinson's disease (author's transl)].
    García de Yébenes J; Avila C; Bazán E; García E; Gervás J; Maseda C; Mena M; Muradas V; Ramos JA
    Med Clin (Barc); 1982 Apr; 78(7):259-64. PubMed ID: 7087591
    [No Abstract]   [Full Text] [Related]  

  • 6. The thyrotropin--releasing hormone (TRH) stimulation of thyrotropin (TSH) and prolactin (PRL) in normal Thai subjects.
    Himathongkam T; Namking M; Pavasuthipaisit K; Supasri Y; Pitchayayothin N
    J Med Assoc Thai; 1980 Aug; 63(8):454-62. PubMed ID: 6776210
    [No Abstract]   [Full Text] [Related]  

  • 7. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letter: Parkinsonism, growth hormone and prolactin.
    Horrobin DF
    N Engl J Med; 1976 Jun; 294(24):1347. PubMed ID: 1264172
    [No Abstract]   [Full Text] [Related]  

  • 9. [Madopar in the treatment of paralysis agitans: II. TRH activation test, EMG examination and HVA level in cerebrospinal fluid before and after treatment].
    Liu DK
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1980 Apr; 13(4):223-6. PubMed ID: 6790255
    [No Abstract]   [Full Text] [Related]  

  • 10. [Visual evoked potentials in Parkinson disease].
    Luquin MR; Obeso JA; Artieda J; Lacruz F; Martínez Lage JM
    Arch Neurobiol (Madr); 1986; 49(4):213-9. PubMed ID: 3753145
    [No Abstract]   [Full Text] [Related]  

  • 11. [Sleep-waking cycle and the nyctohemeral secretion of prolactin and somatotropin in Parkinson patients. Effect of bromocriptine].
    Passouant P; Besset A
    Bull Acad Natl Med; 1980 Feb; 164(2):134-8. PubMed ID: 7004582
    [No Abstract]   [Full Text] [Related]  

  • 12. Individualizing therapy in patients with disabling Parkinson's disease symptoms.
    Calne DB; Duvoisin RC; Koller WC
    Neurology; 1994 Mar; 44(3 Suppl 1):S8-11. PubMed ID: 8121579
    [No Abstract]   [Full Text] [Related]  

  • 13. Parkinson's disease: progression and mortality in the L-DOPA era.
    Di Rocco A; Molinari SP; Kollmeier B; Yahr MD
    Adv Neurol; 1996; 69():3-11. PubMed ID: 8615142
    [No Abstract]   [Full Text] [Related]  

  • 14. Parkinson's disease.
    Clarke CE; Moore AP
    Am Fam Physician; 2007 Apr; 75(7):1045-8. PubMed ID: 17427619
    [No Abstract]   [Full Text] [Related]  

  • 15. Growth hormone secretion in neurological disorders.
    Martinez-Campos A; Giovannini P; Cocchi D; Zanardi P; Parati EA; Caraceni T; Müller EE
    Adv Biochem Psychopharmacol; 1981; 28():521-40. PubMed ID: 6452036
    [No Abstract]   [Full Text] [Related]  

  • 16. Students' forum. Let's look at a problem: Parkinson's disease.
    Iveson-Iveson J
    Nurs Mirror; 1981 Jul; 153(2):36-7. PubMed ID: 6911662
    [No Abstract]   [Full Text] [Related]  

  • 17. Endurance exercise modulates levodopa induced growth hormone release in patients with Parkinson's disease.
    Müller T; Welnic J; Woitalla D; Muhlack S
    Neurosci Lett; 2007 Jul; 422(2):119-22. PubMed ID: 17590511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selegiline slows the progression of the symptoms of Parkinson disease.
    Pålhagen S; Heinonen E; Hägglund J; Kaugesaar T; Mäki-Ikola O; Palm R;
    Neurology; 2006 Apr; 66(8):1200-6. PubMed ID: 16540603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa therapeutics for Parkinson's disease: new developments.
    LeWitt PA
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S31-4. PubMed ID: 19131040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Disturbance of micturition in Parkinson's disease].
    Sakakibara R; Uchiyama T; Yoshiyama M; Hattori T
    No To Shinkei; 2001 Nov; 53(11):1009-14. PubMed ID: 11761908
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.